Reset filter
Keywords
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

7731 Search results.
Relevance Rating New first Old first

Baseline: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Baseline If already performed at screening, please enter results of screening MRI.

Screening: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 16 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Screening

CHEST X-RAY (AP AND LATERAL) Roche H0650g Breast Cancer - CHEST X-RAY (AP AND LATERAL)

- 5/16/17 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: Chest X-Ray
Study part: Chest X- ray. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Melanoma (Skin) null Registration - Chest X-ray Report Shuttle (CXRS) - 2074545v3.0 - Chest X-ray Report Shuttle (CXRS)

- 1/9/15 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: CCRR MODULE
Chest X-ray Report Shuttle (CXRS) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1232AA1-F528-4C83-E034-0003BA12F5E7

Discontinuation Visit: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Discontinuation Visit

Month 36: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 36

Month 12: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 12

Month 18: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 18

Month 30: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 30

Month 24: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 24

Month 6: MRI Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: MRI
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 6

Eligibility Multiple Sclerosis NCT02485223

- 5/19/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT02485223

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial